{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:08:48Z","timestamp":1792354128596,"version":"4.4.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004070","name":"Khalifa University","doi-asserted-by":"publisher","award":["KU-INT-FSU-2024-8474000696"],"award-info":[{"award-number":["KU-INT-FSU-2024-8474000696"]}],"id":[{"id":"10.13039\/501100004070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009957"],"award-info":[{"award-number":["APP2009957"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tips.2026.02.006","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:25:40Z","timestamp":1773235540000},"page":"355-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Complement dysregulation in multiple sclerosis: emerging mechanisms and translational therapeutic opportunities"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-3459","authenticated-orcid":false,"given":"Nemat","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zikra M.","family":"Zakriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent M.","family":"Woodruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.02.006_bb0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41586-021-03892-7","article-title":"A lymphocyte\u2013microglia\u2013astrocyte axis in chronic active multiple sclerosis","volume":"597","author":"Absinta","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.02.006_bb0010","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1093\/brain\/awae013","article-title":"Imaging chronic active lesions in multiple sclerosis: a consensus statement","volume":"147","author":"Bagnato","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.02.006_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.153089","article-title":"Complement therapeutics in neurodegenerative diseases","volume":"230","author":"Zelek","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.tips.2026.02.006_bb0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","article-title":"Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis","volume":"19","author":"Magliozzi","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-022-02408-y","article-title":"Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics","volume":"19","author":"Kamma","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2026.02.006_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200212","article-title":"Complement activation is associated with disease severity in multiple sclerosis","volume":"11","author":"Oechtering","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.tips.2026.02.006_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1094106","article-title":"Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosis","volume":"17","author":"Evans","year":"2023","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.tips.2026.02.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200361","article-title":"Aberrant complement activation is associated with structural brain damage in multiple sclerosis","volume":"12","author":"Oechtering","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.tips.2026.02.006_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.924734","article-title":"Divergent complement system activation in two clinically distinct murine models of multiple sclerosis","volume":"13","author":"Linzey","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100079","article-title":"The complement system: biology, pathology, and therapeutic interventions","volume":"77","author":"Li","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tips.2026.02.006_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1396520","article-title":"The complement system in neurodegenerative and inflammatory diseases of the central nervous system","volume":"15","author":"Negro-Demontel","year":"2024","journal-title":"Front. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0060","article-title":"C1q and central nervous system disorders","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0065","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.13132","article-title":"Alternative pathway activation: ever ancient and ever new","volume":"313","author":"Liszewski","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.tips.2026.02.006_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970486","article-title":"The role of the complement system in multiple sclerosis: a review","volume":"13","author":"Saez-Calveras","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0080","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement\u2014MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.tips.2026.02.006_bb0085","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acn3.51334","article-title":"Impact of complement activation on clinical outcomes in multiple sclerosis","volume":"8","author":"Keller","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2014-309236.11","article-title":"Complement activation in MS: an immunohistochemical analysis","volume":"85","author":"Ingram","year":"2014","journal-title":"J. Neurol. Neurosurg. Psych."},{"key":"10.1016\/j.tips.2026.02.006_bb0095","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev-immunol-101921-035639","article-title":"Complement in the brain: contributions to neuroprotection, neuronal plasticity, and neuroinflammation","volume":"41","author":"Bohlson","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12974-016-0611-x","article-title":"Complement is activated in progressive multiple sclerosis cortical grey matter lesions","volume":"13","author":"Watkins","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2026.02.006_bb0105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12974-022-02539-2","article-title":"Modulation of C5a\u2013C5aR1 signaling alters the dynamics of AD progression","volume":"19","author":"Carvalho","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2026.02.006_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-025-08713-9","article-title":"Granzyme K activates the entire complement cascade","volume":"641","author":"Donado","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.02.006_bb0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41582-023-00839-6","article-title":"Implications of immunometabolism for smouldering MS pathology and therapy","volume":"19","author":"Bittner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-021-02338-8","article-title":"Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory","volume":"142","author":"Ramaglia","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2026.02.006_bb0125","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.tips.2026.02.006_bb0130","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00401-021-02366-4","article-title":"Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation","volume":"142","author":"Gharagozloo","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.tips.2026.02.006_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2019.12.004","article-title":"Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease","volume":"52","author":"Werneburg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2026.02.006_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105533","article-title":"Complement C3 mediates early hippocampal neurodegeneration and memory impairment in experimental multiple sclerosis","volume":"160","author":"Bourel","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2026.02.006_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1017484","article-title":"The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: a review","volume":"15","author":"Saez-Calveras","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.tips.2026.02.006_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113947","article-title":"C1q inhibits differentiation of oligodendrocyte progenitor cells via Wnt\/\u03b2-catenin signaling activation in a cuprizone-induced mouse model of multiple sclerosis","volume":"348","author":"Gao","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0155","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/glia.20093","article-title":"Murine complement C4 is not required for experimental autoimmune encephalomyelitis","volume":"49","author":"Boos","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.tips.2026.02.006_bb0160","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1038\/s41467-025-58708-3","article-title":"Myeloid lineage C3 induces reactive gliosis and neuronal stress during CNS inflammation","volume":"16","author":"Garton","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.02.006_bb0165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbi.2020.03.004","article-title":"Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis","volume":"87","author":"Hammond","year":"2020","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2026.02.006_bb0170","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.4049\/jimmunol.165.10.5867","article-title":"Attenuation of experimental autoimmune demyelination in complement-deficient mice","volume":"165","author":"Nataf","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0175","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.4049\/jimmunol.0800205","article-title":"Complement factor H, a marker of self protects against experimental autoimmune encephalomyelitis","volume":"182","author":"Griffiths","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molimm.2010.08.007","article-title":"CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model","volume":"48","author":"Ingersoll","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0185","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1016\/j.molimm.2007.02.002","article-title":"Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease","volume":"44","author":"Szalai","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neulet.2005.08.022","article-title":"Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis","volume":"390","author":"Reiman","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.tips.2026.02.006_bb0195","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/1521-4141(200204)32:4<1157::AID-IMMU1157>3.0.CO;2-M","article-title":"Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis","volume":"32","author":"Reiman","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0200","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.4049\/jimmunol.173.7.4708","article-title":"Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis","volume":"173","author":"Boos","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neulet.2009.10.045","article-title":"Deletion of both the C3a and C5a receptors fails to protect against experimental autoimmune encephalomyelitis","volume":"467","author":"Ramos","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.tips.2026.02.006_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40478-018-0536-y","article-title":"Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis","volume":"6","author":"Michailidou","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.tips.2026.02.006_bb0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-5728(98)00169-6","article-title":"Kinetics of anaphylatoxin C5a receptor expression during experimental allergic encephalomyelitis","volume":"91","author":"Nataf","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M","article-title":"Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells","volume":"26","author":"Davoust","year":"1999","journal-title":"Glia"},{"key":"10.1016\/j.tips.2026.02.006_bb0225","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2249.2004.02646.x","article-title":"Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats","volume":"138","author":"Morgan","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1165\/rcmb.2016-0067OC","article-title":"C5L2, the second C5a anaphylatoxin receptor, suppresses LPS-induced acute lung injury","volume":"55","author":"Wang","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.tips.2026.02.006_bb0235","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.4049\/jimmunol.2000778","article-title":"Absence of the C5a receptor C5aR2 worsens ischemic tissue injury by increasing C5aR1-mediated neutrophil infiltration","volume":"205","author":"Wu","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0240","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/s41598-021-86191-5","article-title":"Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis","volume":"11","author":"Oveland","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.02.006_bb0245","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/glia.20551","article-title":"Astrocyte-specific expression of a soluble form of the murine complement control protein Crry confers demyelination protection in the cuprizone model","volume":"55","author":"Briggs","year":"2007","journal-title":"Glia"},{"key":"10.1016\/j.tips.2026.02.006_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108518","article-title":"C1q is essential for myelination in the central nervous system (CNS)","volume":"26","author":"Yu","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.tips.2026.02.006_bb0255","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4049\/jimmunol.167.4.2305","article-title":"C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase\/Akt pathway","volume":"167","author":"Soane","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0260","first-page":"2903","article-title":"The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation","volume":"126","author":"Triantafilou","year":"2013","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.tips.2026.02.006_bb0265","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneuroim.2009.06.006","article-title":"Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival","volume":"213","author":"Tegla","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0270","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.07.009","article-title":"Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection","volume":"180","author":"Rus","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578428","article-title":"Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: could it serve as a valuable marker in clinical practice?","volume":"394","author":"Tortosa-Carreres","year":"2024","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0280","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200270","article-title":"Association of complement factors with disability progression in primary progressive multiple sclerosis","volume":"11","author":"Lunemann","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.tips.2026.02.006_bb0285","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1352458520924590","article-title":"Synaptic and complement markers in extracellular vesicles in multiple sclerosis","volume":"27","author":"Bhargava","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2026.02.006_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577147","article-title":"Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis","volume":"340","author":"H\u00e5kansson","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0295","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1177\/1352458519887905","article-title":"Cerebrospinal fluid complement system biomarkers in demyelinating disease","volume":"26","author":"Zelek","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2026.02.006_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122048","article-title":"Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis","volume":"10","author":"Aeinehband","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2026.02.006_bb0305","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1177\/1352458512438238","article-title":"Systemic complement profiling in multiple sclerosis as a biomarker of disease state","volume":"18","author":"Ingram","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2026.02.006_bb0310","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/jcb.23113","article-title":"Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients","volume":"112","author":"Li","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.tips.2026.02.006_bb0315","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2011.08.018","article-title":"Mannose binding lectin mediated complement pathway in multiple sclerosis","volume":"239","author":"Kwok","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2010.03.014","article-title":"Elevated plasma C4a levels in multiple sclerosis correlate with disease activity","volume":"223","author":"Ingram","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0325","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/brain\/awq085","article-title":"Complement regulator factor H as a serum biomarker of multiple sclerosis disease state","volume":"133","author":"Ingram","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.tips.2026.02.006_bb0330","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ana.21311","article-title":"Homogeneity of active demyelinating lesions in established multiple sclerosis","volume":"63","author":"Breij","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0335","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.1255","article-title":"Immunopathology of secondary-progressive multiple sclerosis","volume":"50","author":"Prineas","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0340","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1034\/j.1600-0404.2000.101002116.x","article-title":"Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system","volume":"101","author":"Jongen","year":"2000","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.tips.2026.02.006_bb0345","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12974-024-03036-4","article-title":"Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes","volume":"21","author":"Kodosaki","year":"2024","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.tips.2026.02.006_bb0350","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbi.2023.06.025","article-title":"Brain and immune system-derived extracellular vesicles mediate regulation of complement system, extracellular matrix remodeling, brain repair and antigen tolerance in multiple sclerosis","volume":"113","author":"Torres Iglesias","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2026.02.006_bb0355","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41593-024-01796-z","article-title":"Cell type mapping reveals tissue niches and interactions in subcortical multiple sclerosis lesions","volume":"27","author":"Lerma-Martin","year":"2024","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2026.02.006_bb0360","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41467-024-46068-3","article-title":"Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation","volume":"15","author":"van den Bosch","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.02.006_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106312","article-title":"Can serum C3\/C4 complement ratio be used in the differential diagnosis of central nervous system demyelinating diseases?","volume":"95","author":"Cakan","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.tips.2026.02.006_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117750","article-title":"Usefulness and analytical performances of complement multiplex assay for measuring complement biomarkers in plasma","volume":"554","author":"Meuleman","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.tips.2026.02.006_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1007102","article-title":"Pitfalls in complement analysis: a systematic literature review of assessing complement activation","volume":"13","author":"Brandwijk","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2026.02.006_bb0380","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2026.02.006_bb0385","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2026.02.006_bb0390","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2026.02.006_bb0395","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1212\/WNL.0000000000203217","article-title":"A phase 2 open-label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington\u2019s disease (HD) (S32.009)","volume":"100","author":"Kumar","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2026.02.006_bb0400","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1212\/WNL.0000000000212033","article-title":"Efficacy and safety of targeted immunotherapy with ANX005 in treating Guillain\u2013Barr\u00e9 syndrome: a phase 3 multicenter study (PL5. 006)","volume":"104","author":"Kroon","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2026.02.006_bb0405","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.neuron.2025.10.022","article-title":"C5aR1+ microglia exacerbate neuroinflammation and cerebral edema in acute brain injury","volume":"114","author":"Zhou","year":"2026","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2026.02.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.153003","article-title":"Targeting C5a inflammation in ALS: ex vivo findings from PMX205 phase Ib trial","volume":"230","author":"Fung","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.tips.2026.02.006_bb0415","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1038\/s41467-024-51163-6","article-title":"C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer\u2019s disease mouse model","volume":"15","author":"Schartz","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2026.02.006_bb0420","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41581-023-00704-1","article-title":"Complosome\u2014the intracellular complement system","volume":"19","author":"West","year":"2023","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726000398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:12:56Z","timestamp":1776150776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726000398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0165614726000398"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.02.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement dysregulation in multiple sclerosis: emerging mechanisms and translational therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}